Efficacy and Safety of Estracyt® in Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates efficacy, safety and quality of life in patients affected by metastatic
breast cancer RH+/ HER2- and treated by estramustine phosphate.